Health
FDA approves first personalized cell therapy for multiple myeloma – STAT
The therapy, developed by Bristol Myers Squibb and Bluebird Bio, will be marketed under the brand name Abecma.
The Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the brand name Abecma by its makers, Bristol Myers Squibb and Bluebird Bio.
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney…
-
General18 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Business23 hours agoThese ASX 200 shares could rise 55% to 65%
-
Noosa News22 hours agoSouth-west Queensland highway closed after truck carrying oxygen cylinders catches fire
-
Noosa News17 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba